Clinical trial · Observational
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
NCT05730010CI-TRIAL-00068510completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Examine whether knowledge of ctDNA negativity influences patient decision-making
- timeFrame
- Once all surveys in the sample size are completed, 6 months anticipated
- description
- Ratings- based analysis will be used to examine whether knowledge of ctDNA negativity increases patient acceptability (and if so, by how much) of no therapy in the adjuvant setting, compared to standard of care capecitabine.
Secondary outcomes (1)
- measure
- Estimate at what degree of benefit a given treatment would be acceptable to patients
- timeFrame
- Once all surveys in the sample size are completed, 6 months anticipated
- description
- When assuming risk of recurrence of ctDNA positivity, we will use ratings- based conjoint analysis to determine part-worth utilities of each attribute - potential toxicity and potential benefit. Comparison of part-worth utilities will be used to estimate at what degree of benefit a given treatment would be acceptable, which will inform future trials.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Self- reported history of non-metastatic breast cancer * Self- reported history of receiving chemotherapy for breast cancer * Self- reported history of chemotherapy completed at least 6 months ago but no more than 10 years ago * Able to complete an online survey * English speaking Exclusion Criteria: N/A
References
Publications (0)
Data not yet available
No reference posted for this study.